Evidence map›Paper›PMID 42377562›Full record

ArticleEuropean journal of pediatrics2026

Alagille syndrome case series: five new variants and two large deletions.

Fatma İlknur Varol, Şükrü Güngör, Cemal Ekici, İbrahim Tekedereli, Mukadder Ayşe Selimoğlu, Selçuk Erdoğan, Emre Gök

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fatma İlknur VarolDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, İnonu University Faculty of Medicine, Malatya, Türkiye. ilknur.varol@inonu.edu.tr.
Şükrü GüngörDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, İnonu University Faculty of Medicine, Malatya, Türkiye.ORCID http://orcid.org/0000-0002-0433-5970
Cemal EkiciDepartment of Medical Biology and Genetics, İnonu University Faculty of Medicine, Malatya, Türkiye.ORCID http://orcid.org/0000-0003-1872-3138
İbrahim TekedereliDepartment of Medical Biology and Genetics, İnonu University Faculty of Medicine, Malatya, Türkiye.ORCID http://orcid.org/0000-0002-3300-8020
Mukadder Ayşe SelimoğluDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, İnonu University Faculty of Medicine, Malatya, Türkiye.ORCID http://orcid.org/0000-0001-8533-8446
Selçuk ErdoğanDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, İnonu University Faculty of Medicine, Malatya, Türkiye.ORCID http://orcid.org/0009-0008-0778-3163
Emre GökDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, İnonu University Faculty of Medicine, Malatya, Türkiye.ORCID http://orcid.org/0000-0001-9458-8076

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alagille syndrome (ALGS) is an autosomal dominant disorder characterized by intrahepatic bile duct insufficiency, cardiac, skeletal, ocular, and characteristic facial features, most commonly caused by pathogenic variants in the JAG1gene and, less frequently, in the NOTCH2 gene. This study aimed to expand the existing literature by reporting novel JAG variants identified in our cohort. This retrospective cross-sectional study included 17 patients diagnosed withALGS between 2010-2025 at the Pediatric Gastroenterology, Hepatology, and Nutrition Clinic of İnönü University Faculty of Medicine. Genetic analysis was performed in 12 patients using JAG1 gene sequencing (n = 6), a targeted cholestasis gene panel (n = 4), or whole-exome sequencing (n = 2). Symptom onset ages ranged from 1 to 150 days. Cholestasis was the most common initial presentation, observed in 13 patients (76.5%). Peripheral pulmonary stenosis was the most frequent cardiac anomaly, identified in 12 patients (70.6%). A molecular diagnosis was established in 12 patients, while five were diagnosed clinically due to the unavailability of genetic testing at presentation. All genetically tested patients harbored pathogenic variants in the JAG1 gene. Ten variants were point mutations and two were large deletions. Five point mutations were classified as novel, as they had not been previously reported in the literature or genomic databases. Additionally, two large deletions involving previously undescribed genomic regions were identified and reported for the first time.

conclusionsAlagille syndrome should be considered in patients with unexplained cholestasis, especially in populations with high rates of consanguineous marriage, and the diagnosis should be confirmed with genetic testing whenever possible. This study introduces 5 novel variants and two major deletions containing previously unidentified genomic regions to the literature for the first time. WHAT IS KNOWN: • Alagille syndrome (ALGS) is a multisystem disorder most commonly caused by pathogenic JAG1 variants. • Syndromic cholestasis requires early multidisciplinary evaluation and genetic confirmation. WHAT IS NEW: • Five point mutations were classified as novel, as they had not been previously reported in the literature or genomic databases. • Two large deletions involving previously undescribed genomic regions were identified and reported for the first time.

Indexed as

Alagille SyndromeJagged-1 ProteinChild, PreschoolCross-Sectional StudiesFemaleGenetic TestingHumansInfantInfant, NewbornMalePoint MutationRetrospective StudiesSequence DeletionJAG1 protein, humanJagged-1 ProteinCholestasisIntrahepatic bile duct paucityJAG1 geneMultisystem disorderPediatric liver disease

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.